CD4+ T Cell-independent Immunity Against Salmonellae
Funder
National Health and Medical Research Council
Funding Amount
$550,226.00
Summary
Salmonella typhimurium is an important pathogen in both developed and developing countries where it causes significant HIV-linked morbidity. There is a pressing need to understand how immunity might be established against this organism that will function when the patient is immunocompromised either through age or through a comorbidity like HIV.
A Randomised Controlled Trial To Evaluate The Effectiveness Of Zoledronate Therapy In Osteonecrosis Of The Hip.
Funder
National Health and Medical Research Council
Funding Amount
$535,441.00
Summary
Osteonecrosis of the hip is an important cause of musculoskeletal disability and finding therapeuticsolutions has proven to be challenging. A wide range of surgical treatments with variable success rates ahve been proposed for the treatment. Non-surgical treatment options are limited and usually result in a poor prognosis. This novel clinical trial research will study the protective value of a bisphosphonate in patients with osteonecrosis of the hip and evaluate the cost-effectiveness.
Molecular Characterization Of Human Caliciviruses Causing Gastroenteritis
Funder
National Health and Medical Research Council
Funding Amount
$173,380.00
Summary
A common cause of outbreaks of vomiting and diarrhoea in the community are small viruses approximately 30 nm in diameter. During outbreaks of such viral gastroenteritis, large numbers of people may become ill. The viruses may be transmitted in contaminated food or drink, or passed from person to person. Outbreaks have been associated with hospital wards, nursing homes, school camps, cruise ships and airline flights. The viruses causing these outbreaks are human caliciviruses. They have a structu ....A common cause of outbreaks of vomiting and diarrhoea in the community are small viruses approximately 30 nm in diameter. During outbreaks of such viral gastroenteritis, large numbers of people may become ill. The viruses may be transmitted in contaminated food or drink, or passed from person to person. Outbreaks have been associated with hospital wards, nursing homes, school camps, cruise ships and airline flights. The viruses causing these outbreaks are human caliciviruses. They have a structural resemblance to the rabbit virus recently released in Australia, but possess an alternative host range, and they produce different symptoms in the infected host. The human caliciviruses are difficult to study in the laboratory. They do not replicate in cell culture systems and no animal is known to show symptoms of infection. In this project, the techniques of genetic engineering are being used to develop diagnostic reagents for the viruses, and to study the functions of the proteins encoded by the viral genes. In the longer term, it may be feasible to develop vaccines and drugs against these viruses, but first it is necessary to discover how many types are circulating world-wide and in Australia, and to identify potential targets for antiviral drugs during virus replication.Read moreRead less
VITATOPS - A Randomised Controlled Trial Of Vitamins To Prevent Stroke
Funder
National Health and Medical Research Council
Funding Amount
$391,364.00
Summary
A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS ....A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS study arises from a large body of consistent, biologically plausible evidence linking homocysteine in a dose-dependent fashion to stroke and other types of vascular disease. A simple, non-toxic, and inexpensive intervention in the form of multivitamins (folate, B6 and B12) has been shown to be highly effective at reducing homocysteine levels, irrespective of the underlying cause. All patients who are referred to a neurologist or general physician in one of the collaborating centres within six months of a stroke or transient ischaemic attack are eligible for the trial. In total, treatment will continue for a period of between 1 and 5 years. During this time, patients will be closely monitored in order to record the occurrence of any vascular events (particularly strokes and heart attacks). Neither the study investigator nor the patient will know which treatment they are receiving (i.e. it is 'double blind'). The number of vascular events in the treatment groups will be compared at the end of the study in order to determine whether vitamin treatment is beneficial. This application is for five years of support to allow the investigators to move from the pilot phase of VITATOPS in Perth to begin recruitment to the definitive trial in other centres across Australia and New Zealand. This study may have a major impact on patient management. If vitamins prove to be effective, we may recommend vitamin supplementation to all of our stroke patients in the future.Read moreRead less
Radioimmunotherapy is an experimental method of cancer treatment, involving the use of radioactive isotopes, which are targeted to tumour cells using specific molecules as carriers. These carriers are known as anti-tumour antibodies, and they bind specifically to tumour cells. Recent advances in molecular biology and in the understanding of the nature of tumour cells has resulted in the development of improved anti-tumour antibodies, and such improvements can be expected to continue. However, th ....Radioimmunotherapy is an experimental method of cancer treatment, involving the use of radioactive isotopes, which are targeted to tumour cells using specific molecules as carriers. These carriers are known as anti-tumour antibodies, and they bind specifically to tumour cells. Recent advances in molecular biology and in the understanding of the nature of tumour cells has resulted in the development of improved anti-tumour antibodies, and such improvements can be expected to continue. However, this project is concerned not with the tumour targeting aspect of radioimmunotherapy, but rather with the payload or cytotoxic mechanism, in which the radiation damage is focused on the DNA of the cell. In summary, the project explores a new approach in cancer radioimmunotherapy. This approach will be evaluated firstly in cultures of tumour cells and then in mice bearing transplanted tumours. If successful this project will result in the development of a new cell kill technology that can be combined with different anti-tumour antibodies.Read moreRead less